Evidence map›Paper›PMID 41282927›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Robust CD4

Eric M Jurgens, Sneha Mitra, Kevin Herrera, David Nemirovsky, Brenden Bready, Andriy Derkach, Kinga Hosszu, Devin McAvoy, Ross S Firestone, Sridevi Rajeeve and 20 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Eric M JurgensAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Sneha MitraComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Kevin HerreraCenter for Cell Engineering, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
David NemirovskyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Brenden BreadyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Andriy DerkachDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Kinga HosszuImmune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Devin McAvoyImmune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Ross S FirestoneMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Sridevi RajeeveCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Alexander M LesokhinCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.ORCID 0000-0001-9321-702X
Neha KordeMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Carlyn R TanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Hamza HashmiCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Hani HassounCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.ORCID 0000-0002-2036-1749
Kylee MaclachlanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Urvi A ShahMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.ORCID 0000-0001-8419-1091
Malin HultcrantzMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Maximilian MerzCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Francesco MauraMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Sergio A GiraltAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Gunjan ShahAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Heather J LandauAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Michael ScordoAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Bianca D SantomassoDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center; New York, NY, USA.ORCID 0000-0001-9423-4059
Jae ParkCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Christina LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Saad Z UsmaniAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Karlo PericaCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Sham MailankodyCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
CLINICAL SCHOLARS BIOMEDICAL RESEARCH TRAINING PROGRAMT32CA009512 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Ping Chi · 1985 to 2026
$6.3M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA009512
6 · The paper itself

Abstract

Non-ICANS neurotoxicities (NINTs) are serious, atypical toxicities associated with ciltacabtagene autoleucel, a commercial chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory multiple myeloma. Risk factors contributing to the development of NINTs are poorly understood. In a cohort of 109 patients, we identify predisposing risk factors and propose strategies to mitigate NINTs. We show that high peak absolute lymphocyte count is a strong NINT predictor which directly correlates with flow cytometry-based peripheral blood CAR T cell quantitation. The observed CAR lymphocytosis was polyclonal with a bias towards CD4

Identifiers

PMID41282927
PMCPMC12636671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.